Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
90.86 CHF | -8.92% |
|
-.--% | -.--% |
12:55pm | Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment | DJ |
11:03am | Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study | MT |
Sales 2024 * | 4.64TCr 4.96TCr 4.45TCr 4,13800Cr | Sales 2025 * | 4.99TCr 5.34TCr 4.79TCr 4,45700Cr | Capitalization | 11TCr 12TCr 11TCr 10,13200Cr |
---|---|---|---|---|---|
Net income 2024 * | 708.2Cr 757.9Cr 679.91Cr 63TCr | Net income 2025 * | 869.1Cr 930.09Cr 834.38Cr 78TCr | EV / Sales 2024 * | 2.6 x |
Net Debt 2024 * | 699.18Cr 748.25Cr 671.25Cr 62TCr | Net Debt 2025 * | 236.85Cr 253.48Cr 227.39Cr 21TCr | EV / Sales 2025 * | 2.32 x |
P/E ratio 2024 * |
16.3
x | P/E ratio 2025 * |
13.1
x | Employees | - |
Yield 2024 * |
4.26% | Yield 2025 * |
4.48% | Free-Float | 87.13% |
Latest transcript on Sanofi
1 day | -8.92% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 01/19/01 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 01/22/01 |
Chief Tech/Sci/R&D Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 01/14/01 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 22/20/22 |
Frédéric Oudéa
CHM | Chairman | 60 | 02/22/02 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.61% | 81TCr | |
+43.59% | 64TCr | |
-6.33% | 35TCr | |
+20.62% | 33TCr | |
+10.44% | 30TCr | |
+17.51% | 25TCr | |
+2.33% | 22TCr | |
+12.47% | 22TCr | |
+8.61% | 17TCr |
- Stock Market
- Equities
- SAN Stock
- SAN Stock